Active, not recruitingPhase 3NCT03737214
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
Studying Fabry disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Idorsia Pharmaceuticals Ltd.
- Principal Investigator
- Clinical TrialsIdorsia Pharmaceuticals Ltd.
- Intervention
- Lucerastat(drug)
- Enrollment
- 107 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2029
Study locations (30)
- University of Alabama at Birmingham - Nephrology Research Clinic, Birmingham, Alabama, United States
- University of California Irvine, Irvine, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- University of Florida Clinical and Translational Science Institute, UF Clinical Research Center, Gainesville, Florida, United States
- Rush University Medical Center - Dept of Pediatrics, Chicago, Illinois, United States
- University of Iowa Stead Family Children's Hospital - Division of Medical Genetics, Iowa City, Iowa, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Infusion Associates, Grand Rapids, Michigan, United States
- University of Pennsylvania - Dept of Medicine, Philadelphia, Pennsylvania, United States
- Greenwood Genetics Center, Greenville, South Carolina, United States
- Renal Disease Research Institute LLC, Dallas, Texas, United States
- Baylore University Medical Center, Dallas, Texas, United States
- University of Utah - Division of Medical Genetics, Clinical Genetics Research, Salt Lake City, Utah, United States
- Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax, Virginia, United States
- Royal Perth Hospital, Department of Nephrology, Perth, Perth, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03737214 on ClinicalTrials.govOther trials for Fabry disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06906367A Study of Patients With Fabry Disease (US Specific)Amicus Therapeutics
- RECRUITINGPHASE3NCT06904261A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsAmicus Therapeutics
- RECRUITINGNCT07235709Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR StudyYonsei University
- RECRUITINGNANCT07187440A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseTakeda
- ENROLLING BY INVITATIONNANCT07495410Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FITGeneral University Hospital, Prague
- RECRUITINGPHASE2, PHASE3NCT06328608A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseChiesi Farmaceutici S.p.A.
- RECRUITINGNANCT07382128Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy PhenotypesIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06941025Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingChiesi Farmaceutici S.p.A.